Pharmaceutical giant Eli Lilly (NYSE: LLY) has successfully concluded the purchase of US-based Dice Therapeutics (NASDAQ: DICE) by acquiring 88.4% of the company’s issued and outstanding shares in a transaction valued at $2.0 billion. This strategic acquisition allows Lilly to incorporate Dice’s Delscape platform, which is focused on the development of immunology candidates for chronic diseases.
Enhancing Lilly’s Immunology Pipeline
The acquisition includes two leading oral IL-17 small-molecule inhibitors (SMIs) that are currently in human trials, as well as investigational drugs targeting integrin α4ß7 for inflammatory bowel disease (IBD). These additions to Lilly’s portfolio are expected to bolster its research and development efforts in immunology, a therapeutic area of significant importance in addressing chronic diseases.
Strategic Integration of Dice’s Delscape Platform
Dice’s Delscape platform is known for its innovative approach to identifying and developing novel therapeutic candidates. By integrating this platform, Eli Lilly aims to enhance its capabilities in discovering and advancing new treatments for chronic conditions, particularly in the field of immunology.-Fineline Info & Tech
